Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study
Febuxostat use is associated with a significantly greater risk of mild-to-moderate perturbation of liver function compared to benzbromarone in patients with gout.
Authors
- Xinde Li (ORCID: https://orcid.org/0000-0002-1529-4537)
- Lingling Cui (ORCID: https://orcid.org/0000-0003-1367-5851)
- Wenyan Sun (ORCID: https://orcid.org/0000-0003-2265-3566)
- Robert Terkeltaub (ORCID: https://orcid.org/0000-0001-5368-7473)
- Nicola Dalbeth (ORCID: https://orcid.org/0000-0003-4632-4476)
- Ying Chen (ORCID: https://orcid.org/0000-0002-5807-1878)
- Xiaoyu Cheng (ORCID: https://orcid.org/0000-0001-5413-2859)
- Changgui Li (ORCID: https://orcid.org/0000-0002-4622-3731)
- Tian Liu
Institutions
- Qingdao University (CN)
- University of Auckland (NZ)
- University of California San Diego (US)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1002/acr.25547
- Citations
- 14
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 21.80
Funders
- Natural Science Foundation of Shandong Province